Jump to content

Calcium acetate/magnesium carbonate

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by BG19bot (talk | contribs) at 06:27, 10 March 2016 (v1.38b - WP:WCW project (Link equal to linktext)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Calcium acetate/magnesium carbonate
Combination of
Calcium acetateMineral supplement
Magnesium carbonateMineral supplement
Clinical data
Trade namesOsvaRen, Renepho
AHFS/Drugs.comUK Drug Information
Pregnancy
category
  • Not tested
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
  (verify)

Calcium acetate/magnesium carbonate is a fixed-dose combination drug that contains 110 mg calcium and 60 mg magnesium ions and is indicated as a phosphate binder for dialysis patients suffering from hyperphosphataemia (abnormal high serum phosphorus levels).[1] It is registered by Fresenius Medical Care under the trade names Renepho (Belgium) and OsvaRen (a number of other European countries).

Clinical use

Phosphorus is contained in food with high protein content as well as in processed food. It is absorbed by the small intestine.[2] Healthy kidneys remove excess phosphorus from the body. One of the consequences of renal failure is inadequate removal of phosphorus resulting in increased serum phosphorus levels. This may worsen the overproduction of parathyroid hormone (hyperparathyroidism), and may lead to renal osteodystrophy, calcification of blood vessels and is associated with cardiovascular mortality (the so-called chronic kidney disease-mineral and bone disorder, CKD-MBD).[3] In addition to dialysis therapy and dietary restrictions, a pharmaceutical therapy to lower serum phosphorus levels is recommended.[4]

Mechanism of action

Calcium acetate/magnesium carbonate is taken orally together with the meal.[1] Calcium acetate and magnesium carbonate compounds bind phosphorus derived from food thereby forming indigestible phosphate salts in the intestine that are subsequently excreted with the faeces. The aim of the therapy is to reach a normal serum phosphorus level, i.e. between 0.81 - 1.45 mmol/l (2.5 - 4.5 mg/dl).[3]

Side effects

Side effects from pharmaceutical therapy such as gastrointestinal disorders, e.g. nausea, constipation or diarrhoea may occur, as well as metabolism and nutritional disorders, e.g. hypercalcaemia or hypermagnesaemia.[1]

See also

References

  1. ^ a b c Osvaren – Summary of Product Characteristics; Retrieved on 17 January 2010.
  2. ^ http://lpi.oregonstate.edu/infocenter/minerals/phosphorus/
  3. ^ a b National Kidney Foundation, Kidney Disease Improving Global Outcomes (KDIGO). Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International, Aug. 2009; 42: pp. 1–130.
  4. ^ "What are medications for phosphorus control?". National Kidney Foundation. Retrieved 17 January 2010.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Calcium_acetate/magnesium_carbonate&oldid=709310172"